What is CIPN and what does realistic improvement look like?
Chemotherapy-induced peripheral neuropathy — usually shortened to CIPN — is one of the most common reasons cancer patients seek acupuncture, often after treatment is long behind them.
The acute side effects of chemotherapy — including but not limited to nausea, fatigue, mouth sores — usually resolve within weeks or months. Neuropathy often doesn't. Patients describe burning, tingling, or numbness in the hands and feet that started during chemo and never went away. Some can't button shirts anymore. Some can't feel pedals when they drive. It usually has a great impact on daily life.
CIPN gets less clinical attention than the other side effects because it doesn't often show up with a bang. It develops quietly during treatment and lingers.
What causes it?
CIPN is a direct toxic effect of certain chemotherapy drugs on the peripheral nerves, which promote sensation from your hands and feet back to your spinal cord, and motor signals out to your muscles. The drugs most commonly responsible are taxanes (paclitaxel and docetaxel, used widely in breast, ovarian, and lung cancer protocols), platinum-based agents (oxaliplatin, cisplatin, carboplatin, common in colorectal, ovarian, and other cancers), vinca alkaloids (vincristine, used in lymphomas and some pediatric cancers), bortezomib (used in multiple myeloma), and thalidomide and its derivatives.
Risk rises with cumulative dose. Symptoms often begin during treatment and can worsen for weeks after the last infusion before stabilizing. Many patients improve over time, but some don't improve much at all.
A 2014 systematic review by Seretny and colleagues published in Pain analyzed 31 studies and found that 68% of patients develop CIPN within the first month after chemotherapy, 60% still have symptoms at three months, and 30% are dealing with it at six months or longer. That's a lot of people living with a condition that doesn't have great conventional treatment options.
What are conventional medicine treatments?
The American Society of Clinical Oncology published guidelines on CIPN management in 2020 (Loprinzi et al.), and their conclusions were sobering: no pharmaceutical intervention is recommended for preventing CIPN, and duloxetine — an antidepressant in the SNRI class — is the only medication with appropriate evidence supporting its use in existing CIPN. Benefit is limited.
Gabapentin and pregabalin are sometimes prescribed, but the evidence for treating in CIPN specifically is weak. Topical agents like lidocaine patches and physical therapy are sometimes added. None of these are reliably curative, and many patients find the side effects of duloxetine difficult to tolerate.
This is partly why patients seek out integrative options. There aren't many places to turn.
Acupuncture for CIPN
The evidence for acupuncture and CIPN has strengthened considerably in the past five years. It isn't as well established as the evidence for acupuncture in chemotherapy-induced nausea or aromatase inhibitor joint pain. But it's real, and it's specific.
The pivotal trial was published in 2020 by Ting Bao and colleagues at Memorial Sloan Kettering in JAMA Network Open. They randomized 75 breast cancer survivors with CIPN to either electroacupuncture (twice weekly for eight weeks) or usual care. At week 8, the acupuncture group had a 1.75-point reduction in worst pain scores on a 0–10 scale, compared to 0.19 points for usual care. Numbness and tingling improved significantly. The effect persisted at week 14 and 20 follow-up.
A 2022 randomized controlled trial published in Frontiers in Neurology tested electroacupuncture in 72 colorectal cancer patients receiving oxaliplatin — one of the platinum agents most notorious for neuropathy. The acupuncture group had significantly lower CIPN severity scores and better quality of life measures compared to controls.
Multiple other trials in the past seven years have shown similar findings. A 2023 meta-analysis of randomized controlled trials on acupuncture for neuropathic pain, which included CIPN studies, found moderate-quality evidence for pain reduction. More large-scale trials are needed.
The 2022 Society for Integrative Oncology–ASCO joint guideline on integrative medicine for pain management in oncology (Mao et al., published in Journal of Clinical Oncology) reviewed this evidence and concluded: "Patients with cancer experiencing CIPN may explore use of acupuncture for symptom management." The recommendation was based on two systematic reviews and seven randomized controlled trials.
The 2020 ASCO CIPN guideline had stated insufficient evidence to recommend acupuncture. Two years later, with new trials published, the joint SIO-ASCO guideline changed that position.
Bottom Line: the evidence is real, but not definitive. Not every patient responds. Patients who do respond often see partial rather than complete improvement. Usually, we'll know within six sessions if you’re respondive to treatment.
What treatment actually looks like
A first session for CIPN runs about 75 minutes. I'll ask about which drugs you received, dosage, when symptoms started and how they've changed, where they've spread, and what they're affecting in your daily life. I'll also ask whether you're still in treatment or you're in survivorship, because that changes the approach.
Treatment usually involves points on the affected limbs along with points that support broader nervous system regulation. Electroacupuncture — running a mild electrical current through needles — is standard for CIPN. Most patients describe it as a gentle pulsing or tapping sensation.
For active CIPN — patients still in treatment or recently finished — I usually recommend weekly sessions for the first six weeks, then reassessment. For chronic CIPN — patients years out from treatment — the course tends to be longer and the improvements more gradual. Once we've reached a stable improvement, we can space treatments out over time.
Realistic expectations
A reasonable best case for CIPN treatment is meaningful reduction in symptoms — less burning, better balance, better function — not complete resolution. The Bao trial at Memorial Sloan Kettering saw roughly two-point improvement on a ten-point pain scale. That's the difference between "I can't sleep through the night" and "I can mostly sleep through the night." It's not negligible.
Patients with milder, more recent CIPN tend to do better than patients with severe, chronic CIPN. Patients who start treatment earlier tend to do better than those who wait.
If you're not responding by session six, we revisit our options. Many clients see other benefits from treatment and choose to continue with some frequency if they enjoy it.
When to start
If you're still in active treatment and symptoms are developing, sooner is better. There's evidence from ongoing trials that acupuncture during chemotherapy may reduce the severity of CIPN as it develops, on top of treating other symptoms.
If you're dealing with CIPN and want to talk through whether acupuncture is worth trying for your situation, reach out — I'm glad to answer questions before you book.